Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 3
2002 19
2003 22
2004 58
2005 77
2006 113
2007 139
2008 147
2009 178
2010 166
2011 177
2012 194
2013 204
2014 205
2015 216
2016 212
2017 203
2018 235
2019 221
2020 236
2021 245
2022 4
Text availability
Article attribute
Article type
Publication date

Search Results

2,838 results
Results by year
Filters applied: . Clear all
Page 1
The clinical pharmacokinetics of escitalopram.
Rao N. Rao N. Clin Pharmacokinet. 2007;46(4):281-90. doi: 10.2165/00003088-200746040-00002. Clin Pharmacokinet. 2007. PMID: 17375980 Review.
The absorption of escitalopram is not affected by food. The elimination half-life of escitalopram is about 27-33 hours and is consistent with once-daily administration. ...However, ritonavir, a potent inhibitor of CYP3A4, does not affect the pharmacokinetics of e
The absorption of escitalopram is not affected by food. The elimination half-life of escitalopram is about 27-33 hours and is …
Escitalopram.
[No authors listed] [No authors listed] 2021 Nov 15. Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. 2021 Nov 15. Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. PMID: 30000334 Free Books & Documents. Review.
Escitalopram is the active S-isomer of the antidepressant, citalopram. ...If escitalopram is required by the mother, it is not a reason to discontinue breastfeeding. ...
Escitalopram is the active S-isomer of the antidepressant, citalopram. ...If escitalopram is required by the mother, it is not
A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike?
Sanchez C, Reines EH, Montgomery SA. Sanchez C, et al. Int Clin Psychopharmacol. 2014 Jul;29(4):185-96. doi: 10.1097/YIC.0000000000000023. Int Clin Psychopharmacol. 2014. PMID: 24424469 Free PMC article. Review.
Among the three most widely prescribed SSRIs are paroxetine, sertraline, and escitalopram. Escitalopram is commonly referred to as an SSRI, but also has well-documented allosteric properties, and thus can be further classed as an allosteric serotonin reuptake inhibi …
Among the three most widely prescribed SSRIs are paroxetine, sertraline, and escitalopram. Escitalopram is commonly referred t …
Escitalopram.
Aronson S, Delgado P. Aronson S, et al. Drugs Today (Barc). 2004 Feb;40(2):121-31. doi: 10.1358/dot.2004.40.2.799424. Drugs Today (Barc). 2004. PMID: 15045034 Review.
This chapter reviews preclinical and clinical studies with escitalopram, focusing on its therapeutic profile of action and tolerability. ...Escitalopram is more effective than placebo in the treatment of major depression and as effective as other SSRIs, including ci …
This chapter reviews preclinical and clinical studies with escitalopram, focusing on its therapeutic profile of action and tolerabili …
Clinical pharmacology review of escitalopram for the treatment of depression.
Pastoor D, Gobburu J. Pastoor D, et al. Expert Opin Drug Metab Toxicol. 2014 Jan;10(1):121-8. doi: 10.1517/17425255.2014.863873. Epub 2013 Nov 30. Expert Opin Drug Metab Toxicol. 2014. PMID: 24289655 Review.
The first generic escitalopram was approved in 2012, along with Abbreviated New Drug Applications. The associated cost savings have helped reduce the burden of weighing the benefits of escitalopram over less-expensive alternatives....
The first generic escitalopram was approved in 2012, along with Abbreviated New Drug Applications. The associated cost savings have h …
Escitalopram in Adolescents With Generalized Anxiety Disorder: A Double-Blind, Randomized, Placebo-Controlled Study.
Strawn JR, Mills JA, Schroeder H, Mossman SA, Varney ST, Ramsey LB, Poweleit EA, Desta Z, Cecil K, DelBello MP. Strawn JR, et al. J Clin Psychiatry. 2020 Aug 25;81(5):20m13396. doi: 10.4088/JCP.20m13396. J Clin Psychiatry. 2020. PMID: 32857933 Free PMC article. Clinical Trial.
Vital signs, corrected QT interval, and adverse events were similar in patients who received escitalopram and placebo. CONCLUSIONS: Escitalopram reduces anxiety symptoms, and pharmacogenetics variables influence the trajectory and magnitude of improvement. Variation …
Vital signs, corrected QT interval, and adverse events were similar in patients who received escitalopram and placebo. CONCLUSIONS: …
Efficacy of escitalopram in the treatment of social anxiety disorder: A meta-analysis versus placebo.
Baldwin DS, Asakura S, Koyama T, Hayano T, Hagino A, Reines E, Larsen K. Baldwin DS, et al. Eur Neuropsychopharmacol. 2016 Jun;26(6):1062-9. doi: 10.1016/j.euroneuro.2016.02.013. Epub 2016 Feb 27. Eur Neuropsychopharmacol. 2016. PMID: 26971233 Free article. Review.
A total of 1598 patients from 3 randomised controlled trials were included in the analyses. Escitalopram (n=1061) was superior to placebo (n=537), with an estimated treatment difference on the LSAS of -9.2 points (95%CI: [-14.4; -4.0], p<0.01) (escitalopram 5mg/d …
A total of 1598 patients from 3 randomised controlled trials were included in the analyses. Escitalopram (n=1061) was superior to pla …
Escitalopram plasma levels and antidepressant response.
Florio V, Porcelli S, Saria A, Serretti A, Conca A. Florio V, et al. Eur Neuropsychopharmacol. 2017 Sep;27(9):940-944. doi: 10.1016/j.euroneuro.2017.06.009. Epub 2017 Jun 23. Eur Neuropsychopharmacol. 2017. PMID: 28648553
In detail the correlation between plasma level and efficacy has been much debated. Among first-line drugs for MDD, one of the most used is escitalopram. In the present study we investigated the association between serum concentration of escitalopram (SCE) and antide …
In detail the correlation between plasma level and efficacy has been much debated. Among first-line drugs for MDD, one of the most used is …
Trial of Electrical Direct-Current Therapy versus Escitalopram for Depression.
Brunoni AR, Moffa AH, Sampaio-Junior B, Borrione L, Moreno ML, Fernandes RA, Veronezi BP, Nogueira BS, Aparicio LVM, Razza LB, Chamorro R, Tort LC, Fraguas R, Lotufo PA, Gattaz WF, Fregni F, Benseñor IM; ELECT-TDCS Investigators. Brunoni AR, et al. N Engl J Med. 2017 Jun 29;376(26):2523-2533. doi: 10.1056/NEJMoa1612999. N Engl J Med. 2017. PMID: 28657871 Free article. Clinical Trial.
Escitalopram was given at a dose of 10 mg per day for 3 weeks and 20 mg per day thereafter. ...The lower boundary of the confidence interval for the difference in the decrease for tDCS versus escitalopram (difference, -2.3 points; 95% confidence interval [CI], -4.3
Escitalopram was given at a dose of 10 mg per day for 3 weeks and 20 mg per day thereafter. ...The lower boundary of the confidence i
Escitalopram.
Burke WJ. Burke WJ. Expert Opin Investig Drugs. 2002 Oct;11(10):1477-86. doi: 10.1517/13543784.11.10.1477. Expert Opin Investig Drugs. 2002. PMID: 12387707 Review.
Conversely, R-citalopram is approximately 30-fold less potent than escitalopram at this transporter. Escitalopram has linear pharmacokinetics, so that plasma levels increase proportionately and predictably with increased doses and its half-life of 27 - 32 h is consi …
Conversely, R-citalopram is approximately 30-fold less potent than escitalopram at this transporter. Escitalopram has linear p …
2,838 results